UMIN-CTR Clinical Trial

Unique ID issued by UMIN C000000406
Receipt number R000000494
Scientific Title Clinical effects of azasetoron / dexamethasone combination-therapy on the prevention of nausea and vomiting caused by chemotherapy treatment for colon cancer patients - Comparative cross-over trial between azasetoron single-therapy and azasetoron/dexamethasone combination-therapy -
Date of disclosure of the study information 2006/04/17
Last modified on 2006/04/14 17:46:16

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Clinical effects of azasetoron / dexamethasone combination-therapy on the prevention of nausea and vomiting caused by chemotherapy treatment for colon cancer patients
- Comparative cross-over trial between azasetoron single-therapy and azasetoron/dexamethasone combination-therapy -

Acronym

Comparative cross-over trial between azasetoron single-therapy and azasetoron/dexamethasone combination-therapy

Scientific Title

Clinical effects of azasetoron / dexamethasone combination-therapy on the prevention of nausea and vomiting caused by chemotherapy treatment for colon cancer patients
- Comparative cross-over trial between azasetoron single-therapy and azasetoron/dexamethasone combination-therapy -

Scientific Title:Acronym

Comparative cross-over trial between azasetoron single-therapy and azasetoron/dexamethasone combination-therapy

Region

Japan


Condition

Condition

colon cancer

Classification by specialty

Gastroenterology Hematology and clinical oncology Gastrointestinal surgery

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To compare antiemetic prophylactic effects and safety through the randomized cross-over trial between azasetoron single-therapy and azasetron/dexamethasone combination-therapy for colon cancer patients treated with chemotherapeutic agents such as Irinotecan, Oxaliplatin, Levofolinate and 5-FU

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Pragmatic

Developmental phase

Not applicable


Assessment

Primary outcomes

inhibition rate of vomiting events

Key secondary outcomes

vomiting frequency, score of nausea, patient's feelings (anti-emesis, appetite)


Base

Study type

Interventional


Study design

Basic design

Cross-over

Randomization

Randomized

Randomization unit

Individual

Blinding

Single blind -participants are blinded

Control

Active

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment

Numbered container method


Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

drip-infusion of azasetoron (10mg/body) before the administration of anti-cancer agents (day1)

Interventions/Control_2

drip-infusion of azasetoron (10mg/body) and dexamethason (8mg/body) before the administration of anti-cancer agents (day1)

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

80 years-old >

Gender

Male and Female

Key inclusion criteria

Colon cancer patients to be administered with chemotherapeutic agents such as Irinotecan, Oxaliplatin, Levofolinate or 5-FU (underlying disease: colon cancer)
Patients who have the abilities to agree with this study by themselves, or whose acceptance to this study can be obtained from their proxies in writing

Key exclusion criteria

Patients to receive surgical treatment or irradiation treatment during the term of this study
Patients who develop complications of severe cardiovascular disease, hemodyscrasia, renal disease or hepatic disease.
Pregnant or lactating women
Patients with a history of hypersensitivity to any of the drugs used in this study.

Target sample size

100


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Yasushi Ichikawa

Organization

Yokohama City University Graduate School of Medicine

Division name

Department of Gastroenterological Surgery

Zip code


Address

3-9 Fukuura, Kanazawa-Ku, Yokohama

TEL


Email



Public contact

Name of contact person

1st name
Middle name
Last name

Organization

Yokohama City University Graduate School of Medicine

Division name

Department of Gastroenterological Surgery

Zip code


Address


TEL

045-787-2650

Homepage URL


Email



Sponsor or person

Institute

Yokohama City University Graduate School of Medicine

Institute

Department

Personal name



Funding Source

Organization

Yokohama City University Graduate School of Medicine

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2006 Year 04 Month 17 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Preinitiation

Date of protocol fixation

2006 Year 01 Month 31 Day

Date of IRB


Anticipated trial start date

2006 Year 04 Month 01 Day

Last follow-up date

2008 Year 03 Month 01 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2006 Year 04 Month 14 Day

Last modified on

2006 Year 04 Month 14 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000000494


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name